Background {#Sec1}
==========

Acute leukemia accounts for more than 10,000 deaths annually despite improved treatment regimens and novel cytostatic agents \[[@CR1]\]. Pneumonia due to opportunistic Gram-positive *Staphylococcus* spp., *Bacillus* spp., and *Enterococcus* spp. is one of the leading causes of morbidity in these patients, as well as in patients with other forms of hematological malignancies, because of treatment-induced immunosuppression \[[@CR2], [@CR3]\].

The oral cavity, which hosts more than 700 commensal bacterial species, is the main reservoir of microorganisms that cause aspiration pneumonia \[[@CR4], [@CR5]\]. Thus, investigating the oral microbiome is essential to improve therapeutic strategies, especially for patients with hematological malignancies \[[@CR6]\]. However, most commensal bacteria are not yet culturable, and molecular techniques based on cloning and sequencing the ribosomal 16S RNA have been used instead to identify species in the human microbiome \[[@CR7]\]. Nevertheless, these techniques are prone to false negatives, such as when one bacterial species masks another, and thus underestimate bacterial diversity \[[@CR8], [@CR9]\]. In a previous study, we described *Paenibacillus* sp. strain VT-400, a novel spore-forming bacterium isolated from the saliva of patients with acute lymphoblastic leukemia \[[@CR10]\]. The strain has never been previously detected in humans.

Notably, spore-forming bacteria are poorly studied, and only a few such bacteria have been described and are associated with the human microbiota \[[@CR11], [@CR12]\]. Spores tolerate high temperature, radiation, and noxious chemicals, harbor genes that confer antibiotic resistance, and allow bacteria to survive in unfavorable conditions \[[@CR13], [@CR14]\]. Thus, spores contribute significantly to the persistence of infection and the spread of antimicrobial resistance \[[@CR15]\]. Indeed, prophylactic treatments like oral rinses are poorly effective against spores, and are thus not sufficiently reduce the bacterial load in the oropharynx, or prevent aspiration pneumonia in at-risk patients, especially those with underlying pathologies such as hematological malignancies \[[@CR16], [@CR17]\]. Therefore, identification and characterization of potentially infectious spore-forming microbial species are critical to improve the management or treatment of patients with acute leukemia.

*Paenibacillus* spp. was not known to cause human disease until recent reports implicated *P. alvei*, *P. thiaminolyticus*, and *P. sputi* in respiratory and urinary tract infection, as well as bacteremia in a patient on hemodialysis \[[@CR18]--[@CR20]\]. In this study, we describe *Paenibacillus* sp. strain VT-400, a novel bacterium isolated from the saliva of four children with hematological malignancies, and investigate its potential to cause pneumonia.

Methods {#Sec2}
=======

Bacterial strain {#Sec3}
----------------

*Paenibacillus* sp. strain VT-400 was isolated from the saliva of four children with acute lymphoblastic leukemia who were hospitalized at First Pavlov State Medical University, St. Petersburg, Russia. Unless stated otherwise, the isolate was grown on Columbia agar with 5 % sheep blood (BioMerieux, France) and were stored at −80 °C in Columbia broth (BioMerieux) supplemented with 50 % glycerol. The strain was screened for hemolytic activity by cultivation at 37 °C for 48 h on agar plates supplemented with 5 % sheep blood. Clearing and greenish zones around colonies were considered to indicate β- and α-hemolytic activity, respectively. Primary morphological characterization was performed by light microscopy (Axiostar, Zeiss, Germany), and Gram staining was performed using a kit (Merck, Darmstadt, Germany).

To generate inoculum for infecting mice, the strain was grown at 37 °C for 48 h on Columbia agar with 5 % sheep blood. Colonies picked from the plate were then grown for 18 h at 37 °C in 5 mL Columbia broth. Cells were harvested by centrifugation at 3000×*g* for 15 min (Eppendorf 5415 C centrifuge; Eppendorf Geratgebau GmbH, Hamburg, Germany), and suspended in an isotonic phosphate buffer (0.15 mM, pH 7.2). The turbidity of the suspension was adjusted using a McFarland standard.

Genome annotation and phylogenetic analysis {#Sec4}
-------------------------------------------

Whole-genome sequences from isolates of *Paenibacillus* sp. strain VT-400 were aligned using MUSCLE, and phylogenetic trees were constructed based on the Tamura-Nei distance model in PHYML version 3.0, with 1000 bootstrap replicates \[[@CR21]--[@CR23]\]. The most closely related *Paenibacillus* genomes were included in the analysis. The genome was annotated and mined for virulence factors and antibiotic resistance genes using Rapid Annotation using Subsystems Technology (RAST) and the NCBI Prokaryotic Genome Annotation Pipeline \[[@CR24], [@CR25]\].

Antimicrobial susceptibility testing {#Sec5}
------------------------------------

Susceptibility to antibiotics was determined by the Kirby--Bauer disc diffusion method according to criteria defined by the Clinical and Laboratory Standards Institute \[[@CR26]\]. The strain was tested for susceptibility to 30 µg amoxiclav, 10 μg ampicillin, 10 U penicillin, 30 µg vancomycin, 30 μg cefotaxime, 10 μg erythromycin, 15 μg azithromycin, 10 µg gentamicin, 30 µg amikacin, 30 μg kanamycin, 2 μg clindamycin, 30 μg doxycycline, 5 µg ciprofloxacin, 30 μg neomycin, 30 μg chloramphenicol, 30 μg tetracycline (Becton--Dickinson, USA) and 1.25 μg/23.75 μg trimethoprim-sulfamethoxazole (Oxoid, UK).

Pathogenicity in a mouse infection model {#Sec6}
----------------------------------------

Adult C57BL/6 mice weighing approximately 20 g (Rappolovo, North-West region, Russia) were housed in individual cages in a facility free of known murine pathogens, and were provided feeding ad libitum. Animals were cared for in accordance with National Research Council recommendations, and experiments were executed in accordance with the Guide for the Care and Use of Laboratory Animals \[[@CR27]\].

Animals were randomly designated into two groups of eight, which were used to measure overall survival and bacterial load. Mice were then anesthetized with 2 % isoflurane, and orally instilled with bacterial suspension as previously described \[[@CR28]\]. Briefly, nares were blocked, and mice aspirated 50 µL *Paenibacillus* sp. strain VT400 into the lungs while being held vertically for 60 s. Mice received a total dose of 7.5 log~10~, 8.5 log~10~, or 9.5 log~10~ CFU/mouse. Control mice were treated with sterile 50 µL phosphate-buffered saline. Overall survival was assessed over 7 days, while bacterial load was measured in the lungs and spleen of surviving mice 48 h post infection.

Microbiological assessment of infected lung and spleen {#Sec7}
------------------------------------------------------

Bacterial load in the spleen and lungs was measured 48 h post infection. Briefly, surviving animals in groups designated for this assessment were euthanized by CO~2~ and cervical dislocation. Lungs and spleen were collected and homogenized in 1 mL phosphate-buffered saline. As *Paenibacillus* sp. strain VT-400 was found to be resistant to chloramphenicol and trimethoprim, serial tenfold dilutions of tissue homogenates were plated on Columbia agar with 5 % sheep blood, 5 μg/mL chloramphenicol, and 10 μg/mL trimethoprim (Sigma Chemical Co., St Louis, MO, USA), and cultured at 37 °C. Colonies of spore-forming bacteria were counted after 48 h, and bacterial loads are reported as mean log~10~ CFU/g tissue ± SD. Morphology was characterized by light microscopy (Axiostar, Zeiss), and cells were Gram stained using a kit (Merck).

Ethical approval and consent {#Sec8}
----------------------------

Ethical approval was granted by the First State I. P. Pavlov Medical University Ethics Committee (501/M2013). In accordance with ethical approval, consent to use human biological material was assumed following completion of consent forms.

Statistics {#Sec9}
----------

Survival was compared by Kaplan--Meier analysis log-rank test. Differences in bacterial load were evaluated by one-way analysis of variance in SigmaStat version 2.03 (SPSS, Inc., San Rafael, CA). A *P* value \<0.05 was considered significant.

Results {#Sec10}
=======

Phylogenetic analysis {#Sec11}
---------------------

*Paenibacillus* sp. strain VT 400, which has never been detected in humans before, was isolated for the first time from the saliva of pediatric patients with acute lymphoblastic leukemia. In a previous study, whole-genome sequencing was performed on Illumina HiSeq 2500, with 125-fold average coverage \[[@CR10]\]. Assembly generated 116 contigs spanning 6,986,122 bp, with G+C content 45.8 %.

On the basis of these analyses, the strain was identified as a novel species for which *Paenibacillus* sp. strain VT 400 was assigned, and its genome was deposited in GenBank under accession number LELF01000000. Phylogenetic analysis based on 16S rRNA demonstrated that *Paenibacillus* sp. strain VT 400 is clearly distinguished from other species, as well as from other strains of *P. amylolyticus* (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Dendrogram illustrating the relationship of *Paenibacillus* sp. strain VT 400 to the most closely related *Paenibacillus* sequences deposited in GenBank. The tree is based on partial 16S rRNA sequences \>1400 bp. Bootstrap proportions in 1000 replicates are shown at branch points

Microbiological characteristics of *Paenibacillus* sp. strain VT 400 {#Sec12}
--------------------------------------------------------------------

*Paenibacillus* sp. strain VT 400 is Gram-positive, aerobic, spore-forming, rod-shaped, and motile via peritrichous flagella \[[@CR10]\]. Colonies growing on sheep blood agar are smooth, white pearl in color, and from 0.5 to 1 mm in diameter after 24 h at 37 °C in an aerobic atmosphere. β-hemolysis was observed around colonies growing on blood agar plates. The type strain is deposited in the Deutsche Sammlung fur Mikroorganismen und Zellkulturen (Braunschweig, Germany) under accession number DSM 100755.

Genes encoding virulence factors and in vivo pathogenicity {#Sec13}
----------------------------------------------------------

Analysis of the genome revealed a large number of genes encoding virulence factors that may contribute to pathogenicity (Table [1](#Tab1){ref-type="table"}) \[[@CR29]\]. Most are degradative enzymes and adhesins that may facilitate infection, including proteases, phospholipases, ureases, chitinases, and endopeptidases \[[@CR30]\]. Significantly, we found chemotaxis proteins that were previously shown to contribute to bacterial virulence \[[@CR31]\]. A couple of toxins or putative toxins were also detected, as well as superantigen CD4+ T-cell-stimulating antigen, which causes severe symptoms and septic shock \[[@CR32]\].Table 1Genes encoding virulence factors in *Paenibacillus* sp. strain VT 400CDS no.Functional annotationCDS no.Functional annotation*Toxins or putative toxins*WP_017689222.1Hemolysin DWP_047842244.1CD4+ T-cell-stimulating antigen*Degradative enzymes and adhesins*WP_047843127.1Cell adhesion proteinWP_047843815.1Peptidase M28WP_047841133.1Clp protease *ClpX*WP_047844415.1Peptidase M15WP_047841161.1CAAX proteaseWP_047840296.1Peptidase S9WP_047841788.1Zn-dependent proteaseWP_047840642.1Peptidase S41WP_036605888.1Lon proteaseWP_047840884.1Peptidase TWP_047841635.1ATP-dependent proteaseWP_047841004.1Peptidase C60WP_047842474.1*Clp* protease ATPaseWP_047842822.1Peptidase S8WP_047842474.1RIP metalloprotease *RseP*WP_047843693.1Peptidase M20WP_047843793.1Zinc metalloproteaseWP_047841259.1Peptidase M4WP_047843449.1Alkaline serine proteaseWP_047841848.1Peptidase C15WP_036611272.1O-sialoglycoprotein endopeptidaseWP_047844159.1Peptidase M22WP_047842657.1Oligoendopeptidase FWP_047842036.1Peptidase A24WP_047842959.1EndoglucanaseWP_047842221.1Peptidase M56WP_047841916.1ChitinaseWP_047842221.1Oligopeptidase *PepB*WP_047840281.1AminopeptidaseWP_047842554.1Peptidase EWP_047840267.1Methionine aminopeptidaseWP_047843428.1Peptidase M32WP_047844227.1LysophospholipaseWP_047843333.1Peptidase M29WP_047843070.1Phospholipase DWP_047843711.1Peptidase M1WP_047843459.15′-NucleotidaseWP_047843711.1Peptidase M16WP_047841534.1GDSL family lipaseWP_036610857.1Urease subunit alpha *ureC*WP_047842732.1[d]{.smallcaps}-alanyl-[d]{.smallcaps}-alanine carboxypeptidaseWP_047842024.1Urease subunit beta *ureBFlagella components*WP_036607291.1Flagellar motor protein *MotA*WP_047842476.1Flagellar motor switch protein *FliG*WP_036607292.1Flagellar motor protein *MotB*WP_047842475.1Flagellar M-ring protein *FliF*WP_047842487.1Flagellar biosynthesis protein *FlhA*WP_047840678.1Flagellar synthesis anti-sigma-D factorWP_047842482.1Flagellar basal body rod protein *FlgG*WP_047840677.1Flagellar biosynthesis protein *FlgN*WP_047843392.1Flagellar basal body P-ring biosynthesis protein *FlgA*WP_047840676.1Flagellar hook protein *FlgK*WP_047842488.1Flagellar GTP-binding proteinWP_047840675.1Flagellar hook protein *FlgL*WP_047842486.1Flagellar biosynthesis protein *FlhB*WP_047840661.1Flagellar biosynthesis protein *FliS*WP_047842485.1Flagellar biosynthesis protein *FliQ*WP_036609359.1Flagellar motor switch protein *FliMChemotaxis*WP_047841047.1Chemotaxis protein *CheY*WP_036605799.1Chemotaxis protein *CheC*WP_047842491.1Chemotaxis protein *CheA*WP_036606984.1Chemotaxis protein *CheR*WP_025703561.1Chemotaxis protein *CheW*WP_017689162.1Chemotaxis protein *CheD*

We used a mouse model of pneumonia to study virulence in vivo. Mice were challenged with 7.5 log~10~--9.5 log~10~ CFU, and survival was monitored over 7 days (Fig. [2](#Fig2){ref-type="fig"}). All animals exhibited typical signs of acute infection within 24 h, including hypothermia, piloerection, breathing difficulty, narrowed palpebral fissures, trembling, and reduced locomotor activity. There was a direct correlation between severity of symptoms and dose. Accordingly, mortality depended on dose as well, with mortality observed within 48 h in mice exposed to 8.5 log~10~ and 9.5 log~10~ CFU *Paenibacillus* sp. strain VT 400.Fig. 2Seven-day survival (%) in mice challenged with 7.5 log~10~, 8.5 log~10~, and 9.5 log~10~ CFU of *Paenibacillus* sp. strain VT 400. *Curves* are representative of three independent experiments, with n = 8 in each treatment

Bacterial load was also measured in the lungs and spleen of surviving mice 48 h post infection (Table [2](#Tab2){ref-type="table"}). To confirm the presence of *Paenibacillus* sp. strain VT 400, tissues were homogenized and plated on selective media. Spore-forming bacteria were identified by microscopy. There was approximately 2.47 log~10~ more CFU/g of infected lung tissue in the high-dose group than in the low-dose group (*P* \< 0.05). In addition, the data indicated that *Paenibacillus* sp. strain VT 400 spread from the lungs to the spleen, in which bacterial load was also dose-dependent. Taken together, the data suggest that mortality is due to, at least in part, progressive bacterial invasion and dissemination.Table 2*Paenibacillus* sp. strain VT 400 CFU in the lungs and spleen 48 h post infectionDose (log~10~ CFU/mouse)Log~10~ CFU/g tissue, mean ± SDLungSpleenControl007.50.58 ± 0.280.14 ± 0.258.51.13 ± 0.550.25 ± 0.189.53.05 ± 0.741.20 ± 0.34

Moreover, analysis of the *Paenibacillus* sp. strain VT 400 genome revealed an array of proteins involved in or essential for sporulation (Table [3](#Tab3){ref-type="table"}). Phylogenetic analysis indicated that these genes are conserved and are closely related to other members of the *Bacillaceae* family \[[@CR33]\].Table 3Sporulation factors in the *Paenibacillus* sp. strain VT 400 genomeCDS no.Functional annotation*Stage 0* (*pre*-*septation*)WP_017691423.1Sporulation protein JWP_047842196.1Sporulation protein M*Stage II* (*post*-*septation*)WP_047843799.1Stage II sporulation protein PWP_047840704.1Stage II sporulation protein RWP_017687629.1Stage II sporulation protein M*Stage III* (*engulfment*)WP_024632710.1Stage III sporulation protein DWP_036674989.1Stage III sporulation protein AAWP_036614389.1Stage III sporulation protein ABWP_036614387.1Stage III sporulation protein AEWP_017687241.1Sporulation protein YqfC*Stage IV* (*cortex*)WP_036607700.1Stage IV sporulation protein A*Stage V* (*spore coat*)WP_047844446.1Stage V sporulation protein ACWP_047843814.1Stage V sporulation protein AEBWP_047843753.1Stage V sporulation protein DWP_019424875.1Stage V sporulation protein MWP_017689559.1Stage V sporulation protein SWP_036606123.1Stage V sporulation protein T*Other sporulation proteins*WP_036607856.1Sporulation sigma factor *SigF*WP_017687309.1Sporulation sigma factor *SigG*

Analysis of drug resistance genes and antimicrobial susceptibility testing {#Sec14}
--------------------------------------------------------------------------

Genome analysis also revealed that *Paenibacillus* sp. strain VT 400 harbors different antibiotic resistance genes (Table [4](#Tab4){ref-type="table"}). A total of 96 genes were major facilitator superfamily (MFS) plasma membrane transporters, 18 were multidrug ATP-binding cassette (ABC) transporters \[[@CR34], [@CR35]\]. Four genes were identified as multidrug ABC transporter permeases, eight as multidrug and toxic compound extrusion (MatE) transporters, and two as small multidrug resistance (SMR) proteins \[[@CR36], [@CR37]\]. A multidrug drug metabolite transporter (DMT) was also detected \[[@CR38]\]. Moreover, the *Paenibacillus* sp. strain VT 400 genome also contains genes that confer resistance to specific antibiotics. Finally, genes encoding resistance to tellurium, tunicamycin, and bleomycin were also present. These compounds are used to treat hematological malignancies \[[@CR39], [@CR40]\].Table 4Key antibiotic resistance genes in the *Paenibacillus* sp. strain VT 400 genomeCDS no.FunctionCDS no.FunctionWP_047841924.1\
WP_047840904.1Fosmidomycin resistance proteinWP_047844309.1Multidrug DMT transporterWP_047840644.1Vancomycin resistance proteinWP_047844296.1Multidrug MFS transporterWP_047842579.1Tunicamycin resistance proteinWP_047841225.1Multidrug ABC transporter ATPaseWP_047840788.1Bleomycin resistance proteinWP_047840722.1Multidrug resistance protein SMRWP_036607427.1Fosfomycin resistance protein *FosB*WP_047840931.1Bacteriocin ABC transporter ATPaseWP_047841800.1Tellurium resistance protein *TerA*WP_047844233.1Multidrug transporter MatEWP_047840921.1Tellurium resistance protein *TerF*WP_047844301.1\
WP_047843841.1\
WP_047843528.1Beta-lactamasesWP_026080972.1Macrolide ABC transporter ATP-binding proteinWP_047842226.1Metal-dependent hydrolase, beta-lactamase superfamily IIWP_036615192.1Macrolide transporterWP_047842143.1Aminoglycoside phosphotransferaseWP_047840666.1Cephalosporin hydroxylaseWP_036670493.1Aminoglycoside adenylyltransferaseWP_047843966.1MFS transporterWP_047840993.1Aminoglycoside 3-N-acetyltransferaseWP_047843373.1MFS transporterKLU58081.1Chloramphenicol acetyltransferaseWP_047843512.1MFS transporterWP_047841635.1Tetracycline resistance protein TetAWP_047844079.1Multidrug ABC transporter permeaseWP_036614110.1[d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine ligaseWP_047844020.1Multidrug ABC transporter ATP-binding proteinWP_047843376.1Dihydrofolate reductase

The antibiotic susceptibility of *Paenibacillus* sp. strain VT 400 was then tested against an array of antimicrobials commonly used to treat nosocomial pneumonia \[[@CR41]\]. As can be seen from Table [5](#Tab5){ref-type="table"}, the strain was resistant to macrolides such as erythromycin and azithromycin, as well as to chloramphenicol and trimethoprim-sulfamethoxazole. However, it was sensitive to β-lactams, aminoglycosides, glycopeptides, tetracyclines, lincosamides, and fluoroquinolones.Table 5Antibiotic susceptibility of *Paenibacillus* sp. strain VT 400AntibioticSusceptibilityAmoxiclavSAmpicillinSPenicillinSVancomycinSCefotaximeSErythromycinRChloramphenicolRAzithromycinRGentamicinSAmikacinSKanamycinSClindamycinSDoxycyclineSCiprofloxacinSNeomycinSTetracyclineSTrimethoprim-sulfamethoxazoleR*S* sensitive, *R* resistant

Discussion {#Sec15}
==========

Bacteria that colonize the oral cavity are important pathogenic agents of pneumonia and other opportunistic infections, especially in immunocompromised hosts. We have now identified one such bacterium, *Paenibacillus* sp. strain VT 400, a novel species that was isolated from children with acute leukemia \[[@CR28]\].

Whole-genome analysis indicated that this spore-forming bacterium harbors known virulence factors such as hemolysin, degradative enzymes, adhesins, and flagella. Moreover, CD4+ T-cell-stimulating antigen, a superantigen that causes toxic shock, is also present, along with other virulence determinants such as peptidases, ureases, lipases, and chitinases. Chemotaxis proteins were also found, suggesting that the isolate, which is motile, is capable of chemotaxis \[[@CR42]\].

The detection of a strain such as *Paenibacillus* sp. strain VT 400 in patients with hematological malignancies is a critical result, especially in light of in vivo studies. In these experiments, mice intranasally challenged with at least 8.5 log~10~ CFU of the isolate died from pneumonia, and were found to have infected lungs as well as spleen, indicating dissemination of the infection. Taken together, the data suggest that the strain not only presents genetic features of pathogenic bacteria, but may indeed trigger a life-threatening infection.

In addition, the genome of *Paenibacillus* sp. strain VT 400 features numerous multidrug efflux transporters known to confer intrinsic and acquired resistance to many antibiotics used in clinical practice \[[@CR43]\]. These proteins catalyze uptake, efflux, diffusion, solute exchange, and other mechanisms of bacterial defense against xenobiotics \[[@CR44], [@CR45]\]. In addition, these transporters are not drug-specific and are associated with multidrug resistance \[[@CR46]\].

Moreover, the isolate contains two SMR efflux pumps, which are hallmarks of nosocomial infections and imply that *Paenibacillus* sp. strain VT 400 is most likely a circulating hospital strain, or a strain circulating among hematology patients \[[@CR47]\]. SMR efflux pumps confer nosocomial antibiotic resistance and poor sensitivity to biocidal quaternary ammonium compounds \[[@CR48], [@CR49]\]. Notably, SMR proteins have never been previously found in *Paenibacillus*.

We detected chloramphenicol acetyltransferase, macrolide ABC transporter, vancomycin resistance protein, and *FosB*, which confer resistance to chloramphenicol, macrolide, vancomycin, and fosfomycin, respectively \[[@CR50]--[@CR52]\]. A bacteriocin resistance gene was also found, as were tetracycline resistance genes, including *TetA* \[[@CR53], [@CR54]\]. [d]{.smallcaps}-ala-[d]{.smallcaps}-ala ligase confers cycloserine resistance, while dihydrofolate reductase A is associated with resistance to trimethoprim and trimethoprim-sulfamethoxazole \[[@CR55], [@CR56]\]. In addition, the genome contains resistance genes to β-lactams, including metal-dependent hydrolases, as well as resistance genes to chemotherapeutic drugs.

Nevertheless, many resistance genes of *Paenibacillus* sp. strain VT 400 are not expressed, in accordance with the idea that many mutations do not lead to resistant phenotype \[[@CR57]\]. Sporulation, such as in *Paenibacillus* sp. strain VT 400, preserves and disperses genetic material such as antibiotic resistance genes to overcome harsh environmental conditions \[[@CR58], [@CR59]\]. These spores may be particularly hazardous to immunocompromised patients.

Conclusions {#Sec16}
===========

This study expands the number of poorly characterized *Paenibacillus* spp. that may cause pulmonary disease in humans \[[@CR18]\]. We provide virulence and antibiotic resistance data based on draft genomes and antimicrobial susceptibility testing. We also demonstrate the ability of the strain to trigger pneumonia in vivo, and to invade spleen tissue. Our data may have important implications in the clinic, as the oral microbial flora in patients with hematological malignancies could be a reservoir of pneumonia-causing agents.

Whether *Paenibacillus* sp. strain VT 400 is more prevalent in individuals with acute leukemia remains to be established. However, it is clear that the isolate may have direct clinical implications for patients with therapy-induced immunosuppression. We now intend to determine the prevalence of *Paenibacillus* sp. strain VT 400 among different groups of patients, as well as among patients beyond hematology and bone marrow transplantation units.

Availability of supporting data {#Sec17}
===============================

The complete genome has been deposited in GenBank under the Accession No. LELF01000000. The type strain is deposited in the Deutsche Sammlung fur Mikroorganismen und Zellkulturen under Accession Number DSM 100755.

Conceived and designed experiments: VT, GT. Performed experiments: VT, GT, MV. Analyzed the data: VT, GT, MV. Contributed reagents, materials, and analysis tools: VT, GT. Helped draft the manuscript: GT, MV. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

We thank Albert Tai for performing sequencing at the Genomics Core Facility of Tufts University and for his assistance in completing the project.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.
